arrow_back Back to App

Cannabinoid Safety and Regulation Act: New FDA Rules and Impaired Driving Prevention

This Act establishes a comprehensive regulatory framework for cannabinoid products under the Food and Drug Administration (FDA), including the creation of a new Center for Cannabinoid Products. Citizens will benefit from enhanced safety standards, strict labeling requirements, and a ban on sales to individuals under 21. Furthermore, the legislation allocates funds for research and programs aimed at preventing cannabis-impaired driving, directly impacting road safety.
Key points
Product Safety: The FDA will establish the Center for Cannabinoid Products to oversee manufacturing, testing, and labeling, ensuring products are not adulterated or misbranded.
Consumer Protection: Mandatory, clear labels must disclose THC content, allergens, and risks for special populations (e.g., pregnant women), alongside a prohibition on sales to individuals under 21.
Flavor Ban: Electronic cannabinoid product delivery systems (vaping) are prohibited from containing added artificial or natural flavors (except for terpenes within specified limits).
Road Safety: The Act funds research into cannabis-impaired driving and establishes grant programs for states to enhance prevention and enforcement efforts against driving under the influence of cannabis.
Registration and Penalties: Manufacturers and importers must register with the FDA and comply with good manufacturing practices, with high civil penalties imposed for violations.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_5243
Sponsor: Sen. Wyden, Ron [D-OR]
Process start date: 2024-09-25
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Cannabinoid Safety and Regulation Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_5243.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-09-25.

What are the main provisions?

Key points include:

  • Product Safety: The FDA will establish the Center for Cannabinoid Products to oversee manufacturing, testing, and labeling, ensuring products are not adulterated or misbranded.
  • Consumer Protection: Mandatory, clear labels must disclose THC content, allergens, and risks for special populations (e.g., pregnant women), alongside a prohibition on sales to individuals under 21.
  • Flavor Ban: Electronic cannabinoid product delivery systems (vaping) are prohibited from containing added artificial or natural flavors (except for terpenes within specified limits).
  • Road Safety: The Act funds research into cannabis-impaired driving and establishes grant programs for states to enhance prevention and enforcement efforts against driving under the influence of cannabis.
  • Registration and Penalties: Manufacturers and importers must register with the FDA and comply with good manufacturing practices, with high civil penalties imposed for violations.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Wyden, Ron [D-OR].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Courts and Law Transport